



NDA 201917/S-4

SUPPLEMENT APPROVAL

Vertex Pharmaceuticals, Incorporated
Attention: Mark Swarz
Associate Director, Regulatory Affairs
130 Waverly Street
Cambridge, MA 02139

Dear Mr. Swarz:

Please refer to your Supplemental New Drug Application (sNDA) dated and received December 21, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for INCIVEK[®] (telaprevir), Film-Coated Tablets, 375 mg.

We acknowledge receipt of your amendments dated January 13, 2012, February 2, 2012, April 2, 2012, April 6, 2012, April 12, 2012, June 11, 2012, June 14, 2012, and June 20, 2012.

This "Prior Approval" supplemental new drug application proposes the following changes to the Package Insert and Medication Guide:

1. Contraindications regarding use with Neuroleptic drugs (Section 4);
2. Anemia and Laboratory Test in WARNINGS and PRECAUTIONS (Sections 5.4 and 5.6);
3. Drug Interactions and Clinical Pharmacology with information on raltegravir, buprenorphine and CYP isoenzymes (Sections 7.3 and 12.3);
4. Clinical Studies by revising the definition of SVR and to correct the SVR rates for African American and Cirrhotic subpopulations (Section 14); and
5. The section entitled "Your healthcare provider may need to monitor your therapy more closely if you take INCIVEK with the following medicines. Talk to your healthcare provider if you are taking or starting to take medicines that contain," of the Medication Guide was revised by deleting the drug Desipramine (Norpramin[®]).

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any

new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have questions, call Myung-Joo Patricia Hong, Regulatory Project Manager, at (301) 796-0807.

Sincerely,

{See appended electronic signature page}

Kendall Marcus, M.D.
Deputy Director of Safety
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KENDALL A MARCUS
06/22/2012